<DOC>
	<DOC>NCT00110942</DOC>
	<brief_summary>The purpose of this study is to evaluate the clinical benefit (change in Western Ontario and McMaster University Osteoarthritis Index [WOMAC] pain score) of AMG 108 (300 mg subcutaneously [SC] every 4 weeks) in subjects with OA.</brief_summary>
	<brief_title>Treatment for Patients With Osteoarthritis (OA)</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria Pain defined by a level of greater than or equal to 30 mm on a 100 mm Visual Analogue Scale (VAS) If currently taking any over the counter nutritional supplements, must be on stable doses for greater than 2 months prior to screening If utilizing physical therapy, biomechanical devices or orthotic support, must have been using treatment or device for greater than or equal to 2 months prior to screening If currently or previously taking any nonprescribed supplement (e.g., glucosamine or chondroitin sulphate, shark cartilage, diacerein, soya extract, etc.) must be on stable doses for at least 2 months prior to screening If currently taking nonsteroidal antiinflammatory drugs (NSAIDs), must be on stable doses for at least 2 months prior to screening Able to discontinue NSAIDs at least 5 halflives (approximately 3 days) prior to Day 1 Radiographic evidence of tibiofemoral compartment knee OA within 12 months of screening Signed written informed consent Malignancy within the previous 5 years, except for basal cell or in situ cancer Significant hematologic disease Active infection or history of recurrent or chronic infections Known diagnosis of HIV, hepatitis B, or hepatitis C infection Uncontrolled diabetes or cardiovascular disease and hypertension Inflammatory arthropathy including secondary OA Isolated OA of the patellofemoral joint (bi or tricompartmental involvement are not exclusions) Endstage ("boneonbone") OA (Kellgren Lawrence score of 4) OA of the hip ipsilateral to the index knee Total white cell count less than 2.0 x 10^9/L and/or platelet count less than 100 x 10^9/L observed within 1 month preceding screening Prior intraarticular (IA) injection of anakinra or experimental interleukin1 (IL1) inhibitor therapy Concurrent treatment with SC anakinra Concurrent or recent (less than or equal to 1 month) use of experimental therapy Prior IA corticosteroid injection within 1 month of study Prior viscosupplement therapy within 3 months of study Contraindication(s) to IA injections Subjects who are pregnant or breastfeeding, or plan to become pregnant during the study Subject is not using adequate contraception Known allergy to E coliderived products Unable to understand informed consent Concerns regarding subject's compliance with the protocol procedures Subject will not be available for followup assessment Active substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Intra-articular</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>OA</keyword>
	<keyword>anakinra</keyword>
	<keyword>Amgen</keyword>
</DOC>